Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer M Johnson

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Seminars in Oncology|November 29, 2015
Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid CancerJennifer M Johnson, Stephen Y Lai, Paolo Cotzia, et al.
Cancer Medicine|June 7, 2024
Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinomaAngela E Alnemri, Sruti Tekumalla, Annie E Moroco, et al.
Frontiers in Oncology|December 21, 2020
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment EffectDante J Merlino, Jennifer M Johnson, Madalina Tuluc, et al.
JAMA Otolaryngology-- Head & Neck Surgery|December 18, 2025
Pathologic Response and Survival After Neoadjuvant Immunotherapy for Resectable Mucosal HNSCC: A Systematic Review and Meta-AnalysisEric V Mastrolonardo, Emma De Ravin, Praneet C Kaki, et al.
Cancer|March 12, 2025
Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer typesEric V Mastrolonardo, Pablo Llerena, Emma De Ravin, et al.
Head & Neck|October 9, 2021
Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinomaDavid M Cognetti, Jennifer M Johnson, Joseph M Curry, et al.
The Oncologist|May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland CancersXiuning Le, Christina Baik, Jessica Bauman, et al.
Cancer Medicine|March 23, 2026
Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant ImmunotherapyPablo Llerena, Praneet C Kaki, Kathryn Nunes, et al.
Journal for Immunotherapy of Cancer|July 7, 2021
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumorsRobert H Vonderheide, Kimberly A Kraynyak, Anthony F Shields, et al.
American Journal of Clinical Oncology|November 7, 2019
A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell CancerJianqing Lin, Andrew J Song, Jean Hoffman-Censits, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Seminars in Oncology|November 29, 2015
Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid CancerJennifer M Johnson, Stephen Y Lai, Paolo Cotzia, et al.
Cancer Medicine|June 7, 2024
Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinomaAngela E Alnemri, Sruti Tekumalla, Annie E Moroco, et al.
Frontiers in Oncology|December 21, 2020
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment EffectDante J Merlino, Jennifer M Johnson, Madalina Tuluc, et al.
JAMA Otolaryngology-- Head & Neck Surgery|December 18, 2025
Pathologic Response and Survival After Neoadjuvant Immunotherapy for Resectable Mucosal HNSCC: A Systematic Review and Meta-AnalysisEric V Mastrolonardo, Emma De Ravin, Praneet C Kaki, et al.
Cancer|March 12, 2025
Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer typesEric V Mastrolonardo, Pablo Llerena, Emma De Ravin, et al.
Head & Neck|October 9, 2021
Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinomaDavid M Cognetti, Jennifer M Johnson, Joseph M Curry, et al.
The Oncologist|May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland CancersXiuning Le, Christina Baik, Jessica Bauman, et al.
Cancer Medicine|March 23, 2026
Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant ImmunotherapyPablo Llerena, Praneet C Kaki, Kathryn Nunes, et al.
Journal for Immunotherapy of Cancer|July 7, 2021
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumorsRobert H Vonderheide, Kimberly A Kraynyak, Anthony F Shields, et al.
American Journal of Clinical Oncology|November 7, 2019
A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell CancerJianqing Lin, Andrew J Song, Jean Hoffman-Censits, et al.
Pageof 9